Browse > Article

Dopamine Transporter Density of the Basal Ganglia in Children with Attention Deficit Hyperactivity Disorder Assessed with I-123 IPT PECT  

Ryu, Won-Gee (Department of Diagnostic Radiology, College of Medicine, Yonsei University)
Kim, Tae-Hoon (Department of Diagnostic Radiology, College of Medicine, Yonsei University)
Ryu, Young-Hoon (Department of Diagnostic Radiology, College of Medicine, Yonsei University)
Yun, Mi-Jin (Department of Diagnostic Radiology, College of Medicine, Yonsei University)
Cheon, Keun-Ah (Department of Psychiatry, College of Medicine, Yonsei University)
Chi, Dae-Yoon (Department of Chemistry, Inha University)
Kim, Jong-Ho (Department of Nuclear Medicine, Gachon Medical School)
Choi, Tae-Hyun (Department of Nuclear Medicine, Gachon Medical School)
Lee, Jong-Doo (Department of Diagnostic Radiology, College of Medicine, Yonsei University)
Publication Information
The Korean Journal of Nuclear Medicine / v.37, no.4, 2003 , pp. 235-244 More about this Journal
Abstract
Purpose: Attention deficit hyperactivity disorder (ADHD) has been known as psychiatric disorder in childhood associated with dopamine dysregulation. In present study, we investigated changes in dopamine transporter (DAT) density of the basal ganglias using I-123 N-(3-iodopropen-2-yl) -2-carbomethoxy-3beta-(4-chlorophenyl) tropane [I-123 IPT] SPECT in children with ADHD before and after methylphenidate treatment. Materials and Method: Nine drug-naive children with ADHD and seven normal children were included in the study. We peformed brain SPECT two hours after the intravenous administration of I-123 IPT and made both quantitative and qualitative analyses using the obtained SPECT data, which were reconstructed for the assessment of soecific/nonspecific DAT binding ratios in the basal ganglia. All children with ADHD reperformed [123I]IPT SPECT after treatment with methylphenidate(0.7mg/kg/d) during about 8 weeks. SPECT data reconstructed for the assessment of specific/nonspecific DAT binding ratio of the basal ganglia were compared between before and after treatment methylphenidate. We investigated correlation between the change of ADHD symptom severity assessed with ADHD rating scale-IV and specific/nonspecific DAT binding ratio of basal ganglia. Results: Children with ADHD had a significantly greater specificinonspecific DAT binding ratio of the basal ganglia comparing to normal children(Right : z = 2.057, p = 0.041 : Left : z : 2.096, p = 0.032). Under treatment with methylphenidate in all children with ADHD, specificinonspecific DAT binding ratio of both basal ganglia decreased significantly greater than before treatment with methylphenidate (Right : t = 3.239, p = 0.018 ; Left : t = 3.133, p = 0.020). However, no significant correlation between the change of ADHD symptom severity scores and specific/nonspecific DAT binding ratio of the basal ganglia were found. Conclusions: These findings support the complex dysregulation of the dopaminergic neurotransmitter system in children with ADHD.
Keywords
I-123 IPT; SPECT; Attention Deficit Hyperactivity disorder; Basal ganglia; Dopamine transporter; Methylphenidate;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry 1997；2：311－3
2 Rapport M, Denney C, DuPaul G, Gardner M. Attention deficit disorder and methylphenidate： normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiatry 1994；33：882－93
3 Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999；354：2132－3
4 Swanson J, Castellanos FX, Murias M, LaHoste G, Kennedy J. Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Curr Opin Neurobiol 1998；8：263－71
5 Jensen PS, Mrazek D, Knapp P. Evolution and revolution in child psychiatry：ADHD as a disorder of adaptation. J Am Acad Child Adolesc Psychiatry 1997；36：1672~9
6 Amen DG, Carmichael BD. High－resolution brain SPECT imaging in ADHD. Ann Clin Psychiatry 1997；9：81－6
7 Lou HC, Henriksen L, Bruhn P, Borner H, Bieber Nielsen J. Striatal dysfunction in attention deficit and hyperkinetic disorder. Arch Neurol 1989；46：48－52
8 Zametkin AJ, Liebenauer LL, Fitzgerald GA, King AC, Minkunas DV, Herscovitch P, et al. Brain metabolism in teenagers with attention－deficit hyperactivity disorder. Arch Gen Psychiatry 1993；50：333－40
9 Dresel S, Krause J, Krause K－H, LaFougere C, Brinkbaumer K, Kung HF, et al. Attention deficit hyperactivity disorder：binding of [$^99$mTc]TRODAT －1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med 2000；27：1518－24
10 van Dyck CH, Quinlan DM, Cretella LM, Staley JK, Malison RT, Baldwin RM, et al. Unaltered Dopamine Transporter Availability in Adult Attention Deficit Hyperactivity Disorder. Am J Psychiatry 2002；159：309－12
11 Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Jons PH, Cohen RM. High midbrain [$^18$F]DOPA accumulation in children with attention deficit hyperactivity disorder. Am J Psychiatry 1999；156：1209－15
12 Tayler E. The epidmiology of childhood hyperactivity. Oxford：Oxford University Press,1991
13 Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, et al. Selective effects of methylphenidate in attention deficit hyperactivity disorder：a functional magnetic resonance study. Proc Natl Acad Sci U S A 1998；95：14494－9
14 Biederman J, Farone S, Keenan K, Knee D, Tsuang M. Family－genetic and psychosocial isk factors in DSM－III attention deficit disorder. J Am Acad Child Adolesc Psychiatry 1990；29：526－33
15 American Psychiatric Association. Diagnostic and Statistical Manual of Mental disorder, 4th Edition. APA press, Washington, D.C. 1994
16 Goodman R, Stevenson J. A twin study of hyperactivity：II. The aetiological role of genes, family relationships, and perinatal adversity. J Child Psychol Psychiatry 1989；30：691－709
17 Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE et al. Association of attention －deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995；56：993－8
18 Sieg KG, Gaffney GR, Preston DF, Hellings JA. SPECT brain imaging abnormalities in attention deficit hyperactivity disorder. Clin Nucl Med 1995；20：55－60
19 Cheon KA, Ryu YH, Namkoong K, Kim CH, Lee JD. Dopamine transporter density of the basal ganglia assessed with [$^123$I]IPT SPECT before and after methylphenidate treatment in Children with Attention Deficit Hyperactivity Disorder. Korean J psychopharmacol 2002；13(2)：1－9
20 Biederman J, Newcorn J, Sprich S. Co－morbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991；148：564－77
21 Chang LT. A method for attenuation correction in ratio nuclide computed tomography. IEEE Trans Nucl Sci 1978：25；638－43
22 Greenhill LL. Pharmacologic treatment of attention deficit hyperactivity disorder. Psychiatr Clin North Am 1992；15：1－27
23 Rapport M, Denney C, DuPaul G, Gardner M. Attention deficit disorder and methylphenidate： normalization rates, clinical effectiveness, and response prediction in 76 children. J Am Acad Child Adolesc Psychiatry 1994；33：882－93